Canaccord Genuity Maintains Buy on Apogee Therapeutics, Raises Price Target to $130

Benzinga Newsdesk www.benzinga.com Positive 82.2%

Neg 0% Neu 0% Pos 82.2%

Canaccord Genuity analyst Edward Nash maintains Apogee Therapeutics (NASDAQ:APGE) with a Buy and raises the price target from $89 to $130.